Literature DB >> 8982778

Fel d 1 peptides: effect on skin tests and cytokine synthesis in cat-allergic human subjects.

F E Simons1, M Imada, Y Li, W T Watson, K T HayGlass.   

Abstract

We tested peptide immunotherapy in cat-allergic humans, using a formation of two synthetic peptides, IPC-1 and IPC-2, each of which is 27 amino acids long and contains T cell-reactive regions of Fel d 1, the major cat allergen. In this exploratory, randomized, double-blind, parallel-group study, 42 subjects received s.c. injections of treatment peptides 250 micrograms or placebo weekly for four consecutive weeks. Changes in immediate- and late-phase skin test reactivity, and in antigen-driven cytokine synthesis were assessed. Epicutaneous (end-point titration) and intradermal tests were performed with cat extract (ALK SQ Cat Hair) containing Fel d 1, before the first injection, then 2, 6 and 24 weeks after the fourth and last injection of peptides or placebo. IL-4, IL-10 and IFN-gamma expression by circulating peripheral blood mononuclear cells (PBMC) in response to cat extract was measured using short-term bulk culture of PBMC and short-term limiting dilution analysis. Subjects who received peptide immunotherapy did not tolerate significantly more cat extract containing Fel d 1 in the skin tests 2, 6 or 24 weeks after the last injection than they did at baseline, and their late-phase responses did not decrease significantly compared to baseline. Substantial IL-4, IL-10 and IFN-gamma responses were observed following primary culture of cat antigen-stimulated PBMC; however, the intensity of cytokine synthesis and the IFN-gamma: IL-4 ratio were unchanged in peptide- and placebo-treated groups 6 and 24 weeks after the last injection. A few hours after the injections, subjects receiving peptides reported more allergic rhinitis and asthma symptoms and more pruritus than those receiving placebo. We conclude that under the conditions tested, peptide immunotherapy did not reduce immediate- or late-phase skin reactivity to cat extract containing Fel d 1 or modify cat antigen-specific cytokine production significantly.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8982778     DOI: 10.1093/intimm/8.12.1937

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  29 in total

Review 1.  The potential of peptide immunotherapy in allergy and asthma.

Authors:  F Runa Ali; A Barry Kay; Mark Larché
Journal:  Curr Allergy Asthma Rep       Date:  2002-03       Impact factor: 4.806

Review 2.  Inhibition of human T-cell responses by allergen peptides.

Authors:  M Larché
Journal:  Immunology       Date:  2001-12       Impact factor: 7.397

Review 3.  Recombinant allergen immunotherapy: clinical evidence of efficacy--a review.

Authors:  Melina Makatsori; Oliver Pfaar; Ramon Lleonart; Moises A Calderon
Journal:  Curr Allergy Asthma Rep       Date:  2013-08       Impact factor: 4.806

Review 4.  Immunotherapy in asthma.

Authors:  J A Douglass; F C Thien; R E O'Hehir
Journal:  Thorax       Date:  1997-08       Impact factor: 9.139

Review 5.  Utility and Comparative Efficacy of Recombinant Allergens Versus Allergen Extract.

Authors:  Hardik D Patel; Jeffrey M Chambliss; Meera R Gupta
Journal:  Curr Allergy Asthma Rep       Date:  2017-08-18       Impact factor: 4.806

Review 6.  [Allergen-specific immunotherapy in pet allergy - an update].

Authors:  U Raap; M Wagenmann; O Pfaar
Journal:  Hautarzt       Date:  2011-09       Impact factor: 0.751

7.  Immune response modulation by recombinant peptides expressed in virus-like particles.

Authors:  E V Svirshchevskaya; L Alekseeva; A Marchenko; N Viskova; T M Andronova; S V Benevolenskii; V P Kurup
Journal:  Clin Exp Immunol       Date:  2002-02       Impact factor: 4.330

Review 8.  Recombinant allergens: the present and the future.

Authors:  Marek Jutel; Katarzyna Solarewicz-Madejek; Sylwia Smolinska
Journal:  Hum Vaccin Immunother       Date:  2012-10-01       Impact factor: 3.452

9.  Immunotherapy with allergen peptides.

Authors:  Mark Larché
Journal:  Allergy Asthma Clin Immunol       Date:  2007-06-15       Impact factor: 3.406

Review 10.  Allergen immunotherapy with cat allergen peptides.

Authors:  A Barry Kay; Mark Larché
Journal:  Springer Semin Immunopathol       Date:  2003-09-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.